How to get your head around optimal sequencing in RRMM?
Agoston Gyula Szabo , MD
Righospitalet Copenhagen, Hematologist,Department of Hematology, Denmark
The treatment options in Myeloma have increased significantly over the last decade. Great news for patients and physicians but at the same time adding a lot of complexity in choosing the right therapy for a specific patient at a certain point in time. This e-learning module zooms in on treatment sequencing.
Approximate time: 1,5 hour
Module 1: How to get your head around optimal sequencing in RRMM?
Accredited for 1 CME point
Inger Nijhof, MD, PhD
Hematologist,
St. Antonius Hospital,
Department of Internal Medicine,
The Netherlands
Fredrik Schjesvold, MD, PhD
Hematologist,
Oslo Myeloma Center,
Department of Hematology,
Norway
Isabelle Vande Broek, MD, PhD
Hematologist,
Vitaz, Sint-Niklaas,
Department of Oncology & Hematology,
Belgium
Agoston Gyula Szabo , MD
Hematologist,
Righospitalet Copenhagen,
Department of Hematology,
Denmark
Ville Varmavuo, MD, PhD
Chief Medical Officer in Education,
Kotka,
Internal Medicine,
Finland
Prof. Xavier Leleu, MD, PhD
Hematologist,
Academic Hospital of Poitiers,
France
Valdas Peceliunas, MD
Hematologist,
Vilnius University Hospital Santaros Klinikos,
Department of Hematology,
Lithuania
Accreditation
Accreditation for this e-learning has been granted for 3 points by:
European Accreditation Council for Continuing Medical Education (EACCME)
Obtain CME points
To obtain CME points, you must answer at least 70% of the questions in the final test correctly. If you have a lower score, you can retake the final test twice more. You can pause the e-learning and then resume where you paused.
Clinical cases
Throughout the e-learning challenging clinical cases from daily practice are being presented by the International Expert Panel.